STUDY PROTOCOL

Resistance to single dose albendazole and reinfection with intestinal helminths among children ages 2 to 11 years from the Peruvian Amazon region: a study protocol

Greisi Curico1, Paul García-Bardales1, Tackeshy Pinedo1, Wagner Shapiama1, Miguel Moncada-Yaicate1, Lucero Romaina1, Pablo P. Yori2, Maribel Paredes-Olortegui1, Graciela Meza-Sánchez3, Andrés G. Lescano4, Valerie A. Paz-Soldan5, Francesca Schiaffino1, Richard A. Oberhelman5* and Margaret N. Kosek2

Abstract

Background: Deworming programs aimed at reducing morbidity and mortality from geohelminth infections are common in many countries where these infections are endemic, but data demonstrating increasing levels of resistance to albendazole and mebendazole are causes for concern. Studies to evaluate the clinical efficacy of deworming programs are critical to maintain high infection control goals.

Methods: We propose to assess the clinical efficacy of Peruvian national guidelines for deworming programs in a prospective observational study conducted in the Amazon River basin area near Iquitos, Peru. Major outcomes to be evaluated include (1) albendazole resistance of intestinal helminths (trichuriasis, ascariasis, hookworm), and (2) frequency of reinfection with intestinal helminths 4 months after treatment with albendazole. Children ages 2–11 years from the Belén District of Iquitos will be identified based on a community census. Following parental informed consent, demographic data, weight, and height will be recorded and a stool specimen for parasitological exam by direct observation and Kato-Katz concentration method, and helminthic egg counts will be collected prior to administration of albendazole, following Peruvian national guidelines. Follow-up stool specimens examined in the same manner will be collected at 20 days, 90 days, and 100 days following initial administration of albendazole, and based on parasites found repeat treatment will be administered in accordance with national guidelines. Real-time multiplex qPCR will be performed on helminth positive samples collected prior to initial deworming and on helminth-positive specimens detected on day 15–20. A total sample size of 380 participants was calculated based on total population in the target group and prevalence estimates of helminth infections and clinical resistance based on recent data.

Discussion: Data from observational clinical efficacy studies are important to guide geohelminth infection control programs.

*Correspondence: oberhel@tulane.edu
1 Department of Tropical Medicine, Tulane School of Public Health
and Tropical Medicine, 1440 Canal Street, Suite 2310, New Orleans, LA 70112, USA
Full list of author information is available at the end of the article
Background

Worldwide, approximately 1.5 billion people or about 24% of the world’s population, are infected with soil-transmitted helminths (STH) [1]. Soil-transmitted helminth infections are widely distributed in tropical and subtropical areas, especially in sub-Saharan Africa, America, China and East Asia. More than 267 million preschool-age children and more than 568 million school-age children live in areas with intense transmission and are able to benefit from treatment and prevention strategies [2]. In low- and middle-income countries, risk factors for STH infections include poverty and malnutrition, and STH infections have been associated with delays in cognitive, motor, and social development in children under 5 years of age [3, 4]. The presence of helminths also may cause intestinal blood loss with iron deficiency that manifests as anemia, especially in children with hookworm infection [5].

The World Health Organization and the Pan American Health Organization (WHO/PAHO) set standards for the control of soil-transmitted helminthiasis in Latin America and the Caribbean. These organizations recommend deworming strategies such as preventive chemotherapy (PC), which is an important part of a comprehensive package to eliminate morbidity due to soil-transmitted helminths in populations at risk. This strategy is applied according to the prevalence of soil-transmitted helminths in high-risk areas for preschool-age children (1 to 4 years) and school-age children (5 to 14 years) [6]. In high-risk areas with a prevalence of >50%, the recommendation is for treatment twice a year (every 6 months), while in low-risk areas with a prevalence >20 to <50%, once a year (every 12 months) treatment with albendazole (400 mg) or mebendazole (500 mg) is recommended. In Peru, a universal dose is administered to children between 2 and 11 years of age twice a year in primary care health centers [7].

The efficacy of albendazole is variable against Trichuris trichiura compared to other anthelmintics; the cure rate ranges between 2.6 and 64.5% [8] and the egg reduction rate ranges between 7 and 83.1%. However, high cure rates of Trichuris trichiura are observed in some contexts [9–11]. In a study conducted in the Peruvian Amazon, an open-pair randomized trial was conducted in fifth-grade children from 18 primary schools (9 intervention and 9 control). Intensity of Ascaris lumbricoides infection at follow-up was 58% lower in children from intervention schools, a significant reduction as compared to children from control schools (RR=0.42; 95% CI 0.21 to 0.85), but no significant changes were observed in the intensity of hookworm or Trichuris trichiura [12]. In another study from Peru, a total of 1193 school-age children were dewormed with a single dose of Albendazole (400 mg). Of the 909 children who tested positive for at least one STH infection, a random sample of 385 were followed up 2 weeks later with a second stool sample. The efficacy of albendazole was variable, with an egg reduction rate of 99.8% for Ascaris lumbricoides (95% CI 99.3–100); 93.6% for hookworm (95% CI 88.2–96.6), and 72.7% for Trichuris trichiura (95% CI 58.5–79.1) [13]. In many cases treatment with albendazole alone appeared inadequate, especially for Trichuris trichiura. Other interventions such as combined therapy have been evaluated in other contexts. Ivermectin results in higher cure rates than albendazole and is well tolerated. The benefits of ivermectin for helminth infections would depend on the amount of resistance present [14–16].

Large-scale interventions to control soil-transmitted helminth infections at the community level with anthelmintic drugs such as albendazole have the potential to exert selective pressures which may favor the development of drug resistance, which could significantly reduce the benefits provided by deworming programs. Drug resistance in parasitic nematodes is caused by a single nucleotide polymorphism (SNP) in the β-tubulin gene at codon positions 200 (T → A), 167 (T → A) or 198 (A → C) [17].

Herein we describe the protocol for our observational study of a prospectively enrolled cohort to assess clinical resistance to albendazole and reinfection by intestinal helminths in children from the Peruvian Amazon receiving treatment according to Peruvian Ministry of Health treatment guidelines [7], to measure preventive treatment effectiveness for 6 months.

Study design (see Fig. 1)

Prospective cohort study of children aged 2 to 11 years, with an individual time of participation of 4 and a half months.

Participants will be boys and girls ages 2 to 11 years who live in the catchment area of the Centro de Salud 6
| Day 0 | ENROLLMENT PHASE |
|------|------------------|
|      | Community census and assessment of inclusion criteria |
|      | Informed consent and assent |
|      | Epidemiologic data, weight and height measurement |

| Day 1 | FOLLOW-UP PHASE |
|------|------------------|
|      | Parasitologic report (direct observation and Kato-Katz) |
|      | First dose of albendazole (400mg orally) |
|      | UNIVERSAL TREATMENT WITH ALBENDAZOLE BY MINISTRY OF HEALTH GUIDELINES 7 |
|      | No treatment |

| Day 20 | (2nd visit) |
|--------|-------------|
|        | Parasitologic report (direct observation and Kato-Katz) |
|        | Second dose of albendazole (400mg orally) for Ascariis and hookworm or albendazole (400mg orally) + ivermectin (600µg/kg) for Trichuriasis or ivermectin (200µg/kg) x 2 days for Strongyloidesis |
|        | INDIVIDUALIZED TREATMENT BY WORLD HEALTH ORGANIZATION GUIDELINES 2 |

| Day 90 | (3rd visit) |
|--------|-------------|
|        | Parasitologic report (direct observation and Kato-Katz) |
|        | Third dose of albendazole (400mg orally) for Ascariis and hookworm or albendazole (400mg orally) + ivermectin (600µg/kg) for Trichuriasis or ivermectin (200µg/kg) x 2 days for Strongyloidesis |
|        | INDIVIDUALIZED TREATMENT BY WORLD HEALTH ORGANIZATION GUIDELINES 2 |

| Day 130 | (4th visit) |
|---------|-------------|
|         | Parasitologic report (direct observation and Kato-Katz) |
|         | Fourth dose of albendazole (400mg orally) for Ascariis and hookworm or albendazole (400mg orally) + ivermectin (600µg/kg) for Trichuriasis or ivermectin (200µg/kg) x 2 days for Strongyloidesis |
|         | INDIVIDUALIZED TREATMENT BY WORLD HEALTH ORGANIZATION GUIDELINES 2 |

**Fig. 1** Study design
de Octubre, located in the district of Belén, city of Iquitos, and department of Loreto in Peru.

Inclusion criteria:

a. Parental written informed consent, in addition to the verbal and written assent for children ages 6 to 11 years.
b. No antiparasitic treatment in the prior 3 months [18].
c. Permanent residence in the study community, with no plans to move in the next 6 months.

Major outcomes:

1. Albendazole resistance of intestinal helminths (Trichuriasis, Ascariasis, Hookworm, Strongyloides).
2. Reinfection with intestinal helminths 4 months after treatment with Albendazole.

Sample size
Sampling will be carried out throughout the jurisdiction of the 6 de Octubre Health Center, which includes rural, peri-urban and urban areas, with a total potential study population of 3379 children ages 2 to 11 years based on health center databases. Based on this study population of 3379 children aged 2 to 11 years, to measure clinical resistance to albendazole a sample of 380 children was needed. This calculation was made in Epi Info Version 7.2 applying a type I error of 5% and assuming 50% prevalence of helminths in children, 25% frequency of Trichuris trichiura in children with helminths, 50% resistance to albendazole based on detection of any helminth in a follow-up sample and adjusting for 10% loss to follow-up for study participants.

Recruitment of participants
To identify eligible children for the study, a community census is being conducted in the catchment area of the Centro de Salud 6 de Octubre, which includes rural, peri-urban and urban areas. Rural areas are defined as streets located on the opposite side of the Itaya river from the city of Iquitos, which is a flood prone area without basic services, electricity and drinking water. Peri-urban areas are located on the Iquitos side of the river and extend into the river, with houses on stilts or raft houses that float on the surface of the river. Many of these houses already have electricity and drinking water, and they are usually located around the health center. Another part of the study community is located in the urban area of Iquitos, with concrete houses that all basic services and access to food markets, etc.

For enrollment in rural areas, a sweep strategy will be applied, meaning that we will look for children who meet the inclusion criteria throughout the community. For the peri-urban area homes without an address (located on rafts) we will also apply the same strategy. In the peri-urban and urban area where there are well-defined maps with streets and addresses, we will recruit candidates with numerical codes from the community census based on a random number generator, starting from the first block and then moving forward clockwise to the next block.

Once the first randomly selected child of any age between 2 and 11 years has been recruited, enrollment will continue in the same way until the established strata are completed: age 2 years = 36 children; 3 years = 36 children; 4 years = 36; 5 years = 32 children; 6 years = 33 children; 7 years = 34 children; 8 years = 35 children; 9 years = 36 children; 10 years = 33 children; 11 years = 34 children. Once all the blocks of the study community have been sampled, if the target number of participants for each stratum were not completed, the process will be repeated from the beginning and thus complete the corresponding sample for each age group.

Data and specimen collection (see Fig. 1 for overview of study visits and procedures)
Following informed consent, demographic data will be collected, including housing characteristics, general caregiver information, and information on hygiene and childcare. Weight and height measurements will be performed by a member of the on-site investigation team, and a stool collection container will be provided to the caregiver [19]. Fresh feces (10–20 g) will be collected from each participant and the date and time of specimen collection will be recorded upon retrieval. At the end of the day specimens will be transported to the laboratory in a biological sample transport box with ice at the end of the day, for analyses that will be carried out within the next 24 h.

Albendazole treatment and clinical follow-up
Following enrollment and initial stool specimen collection, albendazole 400 mg will be administered orally in accordance with Peruvian Ministry of Health guidelines (RM No. 479-2017-MINSA) as part of the universal treatment policy in Peru. Stool samples for the study will be collected three times after the first stool sample is taken. This means that the same procedures will be repeated at 15 to 25 days, 90 to 100 days and at 130 to 140 days (in order to measure resistance and reinfection at 11%, 50% and 75% of the 6-month interval recommended for
repeating preventive treatment). If parasites are found in samples after treatment with albendazole, individualized treatment will be administered according to World Health Organization standard of care treatment guidelines [2]. For *Ascaris* and hookworm, albendazole 400 mg will be administered as a single oral dose. For *Trichuris trichiura*, ivermectin 600 µg/kg/day will be administered with albendazole 400 mg, both as single oral doses [20, 21]. For *Strongyloides stercoralis*, ivermectin 200 µg/kg/day for 2 days will be administered [22–24].

**Laboratory analysis**

Fecal samples will be analyzed by direct observation of eggs and/or larvae by microscopy and egg counting by the Kato-Katz technique. Direct microscopy is the diagnostic standard in areas with limited resources. The Kato-Katz method is used to estimate the intensity of infection by *Ascaris lumbricoides*, hookworms and *Trichuris trichiura*. Although this method is more sensitive than direct microscopy, it requires more time and labor to detect geohelminth eggs [25, 26]. Once the procedures have been carried out and the results obtained, the remaining stool samples will be aliquoted and stored at −80 °C.

In the second sample, molecular detection of helminths by polymerase chain reaction (qPCR) will be performed on specimens with helminths detected (i.e., clinical resistance) in order to determine the presence of resistance markers at the genetic level.

Direct observation: In a properly labeled slide, 0.5 g of feces will be applied with a wooden applicator and 20 µL of saline solution will be added. The first observation will be made from left to right, then the procedure will be repeated with 20 µL of Lugol’s solution added. Both observations will be made with the 10× and 40× objectives in order to qualitatively identify the absence or presence of helminths (*Ascaris lumbricoides*, *Trichuris trichiura*, hookworms, and *Strongyloides stercoralis*). Kato–Katz method: Two grams of feces will be placed on a smooth and sterile surface, covered with a piece of nylon and pressed with a flat-edge plastic applicator. The filtered feces will then be placed in the center of a 41.7 mg template on a slide until the hole is filled, after which the template will be removed and the sample will be covered with a celophane sheet previously imbued in a glycerol-blue solution of methylene, and pressure will be applied until the sample is distributed homogeneously. After a 30-min incubation, eggs counts will be carried out using the 10× objective and a cell counter, the total number of eggs counts per species will be reported in eggs per gram (epg) and will be multiplied by 24 (41.7 mg template) [27], and the results of each parasite found will be recorded and reported quantitatively. This procedure will be performed on the 4 samples per subject collected throughout the study [28].

**STH infection by qPCR:** To measure the intensity of the infection, quantitative polymerase chain reaction (qPCR) will be used in such a way that the Kato–Katz variability between users is reduced and the sensitivity of the detection of low-grade parasitic infections is increased [29, 30]. Real-time multiplex qPCR will be performed on positive samples (Day 0) for helminths that were identified by direct observation and Kato–Katz for the simultaneous detection of *Ascaris lumbricoides*, *Trichuris trichiura*, *Necator americanus*, *Ancylostoma duodenale*, and *Strongyloides stercoralis* [31]. If the sample from Day 0 is negative, the sample from Day 15 will be analyzed if it is positive for helminths. Amplification will be performed in a Quant Studio 7 Flex thermocycler (Applied biosystems) in a total volume of 25 µL using GoTaq® qPCR Probe Master Mix (Promega, USA) and 5 µL of fecal DNA. There will be two multiplex qPCR assays (STH1 and STH2); STH1 will be used to detect *Ascaris lumbricoides*, *Trichuris trichiura* and *Strongyloides stercoralis*, while STH2 will be used for the 3 species of hookworms. The cycling conditions for both cases will be the following: 1 cycle at 95 °C for 5 min, 40 cycles at 95 °C for 10 s and 1 cycle at 60 °C for 60 s. The primers will be the same ones used by Azzopardi et al. [32] which can be seen in Table 1.

**DNA extraction from STH:** Nucleic acid extraction will be performed using the purification method by column centrifugation and cell disruption by bead beater, which consists of lysing the sample by mechanical disruption. The guidelines of the modified protocol of the QIAmp Fast DNA Stool mini kit (CAT 51604) will be followed, which consists of 4 phases (lysis, filtering, washing and elution), with an approximate time of 60 min for 8 samples. To evaluate the quality of the extraction and the efficiency of the amplification, extrinsic controls (MS2 and PhHV) will be added to each sample during the lysis phase. Subsequently, the DNA obtained will be stored at −20 °C for the following processes or at −80 °C for prolonged storage.

**Statistical analysis**

Data will be analyzed in Access using Stata, using chi square, Fisher’s exact, and Wilcoxon tests to compare
To analyze the data from direct observation and quantification by the Kato-Katz method, descriptive statistics will be used, to report the prevalence found in percentages. For the sociodemographic and clinical data of the study population, measures of central tendency and dispersion will be used for the quantitative variables and measures of relative frequency for the qualitative variables. Comparisons will also be made between sample 1, sample 2, sample 3 and sample 4 to determine the positivity of each species of parasite found using the Yates chi-square test, setting a significance level of \( p < 0.05 \).

The sociodemographic variables will be compared with the parasite load and presence/absence of parasites, using a multiple logistic regression model (univariate t-test), to determine the variables statistically associated with infection by *Ascaris lumbricoides*, *Trichuris trichiura* and hookworms.

The quantification performed with the Kato-Katz method will be compared with the Ct value (Ct threshold) of the multiplex qPCR, by converting Log10 of the absolute egg counts per stool sample, in order to estimate the absolute egg counts in eggs per gram (EPG) in the DNA extractions, using the following formula [33]:

\[
\text{EPG Ascaris} = 10(\text{Ct} - 36.97)/ -3.489,
\]

\[
\text{EPG Trichuris} = 10(\text{Ct} - 36.73)/ -3.288,
\]

\[
\text{EPG } N. \text{americanus} = 10(\text{Ct} - 35.02)/ -3.641,
\]

\[
\text{EPG } A. \text{duodenale} = 10(\text{Ct} - 35.02)/ -3.641.
\]

To determine treatment efficacy, the prevalence will be measured before and after receiving treatment and compared using the Yates chi-square test. For calculations of cure rate and intensity of infection obtained from qPCR, only data from positive results before taking the first dose will be included [34].

The cure rate will be measured using the following formula:

\[
\frac{\# \text{ positive for helminths (pretreatment)} - \# \text{ negative for helminths (post treatment)}}{\# \text{ cases positive for helminths (pretreatment)}} \times 100.
\]

### Table 1 Primers used in multiplex qPCR analysis of stool samples by STH1 and STH2

| qPCR | Target | Primer | Sequence (5′–3′) | Size (bp) | Gene detected | Final conc. (nM) |
|------|--------|--------|-----------------|-----------|---------------|-----------------|
| STH1 | Strongyloides stercoralis | Strongy-F | GAATTCCAAGTAAACGTAAGTCATTAGC | 101 | 18S | 100 |
| | | Strongy-R | TGCCCTGTGATTGTGTCAGTTC | 100 | |
| | | Strongy-P | FAM-ACACACCGGZEN/CCGTGCTGC-IBFQ | 50 | |
| STH1 | Trichuris trichiura | Tri-F | TTGAAACGACTTGTCTCAACTT | 76 | 18S | 100 |
| | | Tri-R | CGTATTCTGTTAAACGTGGTC | 100 | |
| | | Tri-P | CY5-CGATGGTAC/TACGGTACCTACCA-TGG-IBFQ | 50 | |
| STH1 | Ascaris lumbricoides | Asc-F | GATAATACGTCGGCGGTTCCTT | 87 | Internal transcribed spacer | 100 |
| | | Asc-R | GCCAAACATGGCCACATTC | 100 | |
| | | Asc-P | HEX-TGGCGGAC-ZEN/AATTGCGACGTGAT-IBFQ | 50 | |
| STH2 | Ancylostoma spp. | Anc-F | CCGGAAGGTGGAGCATC | 104 | Internal transcribed spacer | 100 |
| | | Anc-R | CGAACCTCCAGCAGACATC | 100 | |
| | | Anc-P | CY5-CATGACCTA-CGACGTGAGG-IBFQ | 50 | |
| STH2 | Necator americanus | Nec-F | CTGTTTGCGAAGCGGACTTGTC | 101 | Internal transcribed spacer | 100 |
| | | Nec-R | ATACACGGGTGCAATGTTGC | 100 | |
| | | Nec-P | CY5-CATGACCTA-CGACGTGAGG-IBFQ | 50 | |
| STH1 Y STH 2 | Phocine herpes virus | Phi-F | CGGCGAATCAGGATGATC | gB gene | 100 | |
| | | Phi-R | CCGTGTCAAGGAAGGCAAA | 100 | |
| | | Phi-P | CY5-TGTGTGTTGCAGAGGCAACAC-IBFQ | 50 | |
Intensity of infection will be measured using the following formula:

\[
\frac{\text{mean egg count (pretreatment) } - \text{mean egg count (post treatment)}}{\text{mean egg count (pretreatment)}} \times 100.
\]

And the calculation of the rate of reduction of eggs by helminth species:

\[
\frac{[1 - \text{mean egg count in EPG (post treatment)}]}{\text{mean egg count in EPG (pretreatment)}} \times 100.
\]

In addition, a comparison of the cycle threshold (Ct) by qPCR will be made using the Student’s t-test for paired samples.

Discussion

Data from observational clinical efficacy studies such as this one are vitally important to assure continued high levels of geohelminth infection control, and to permit re-evaluation of clinical guidelines when necessary to achieve desired program goals.

Acknowledgements

Not applicable.

Author contributions

Study design and protocol development by GC, PGB, TP, WS, GMS, AGL, RAO, and MNK. Laboratory support by PGB, TP, WS, MMY, LR, and PPy. Subject enrollment and field work by MPO, GC, MMY, and LR. Implementation consulting by VAPS and FS. Regulatory and registration support by RAO, MNK, and GMS. All authors read and approved the final manuscript.

Funding

The study protocol reported in this publication was supported by the Fogarty International Center of the National Institutes of Health under Award Number D43TW010913 entitled “Enabling Infectious Disease Research Capacity in the Peruvian Amazon”. AGL is sponsored by Emerge, the Emerging Diseases Epidemiology Research Training grant D43 TW007393 awarded by the Fogarty International Center of the US National Institutes of Health. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The funder was not involved in the study protocol described here.

Availability of data and materials

Data generated from this study will be available from the corresponding author on reasonable request, or published with the final results, after all findings are available. Data will be shared after approval of a proposal by the authors for legitimate scientific purposes.

Declarations

Ethics approval and consent to participate

Approved as protocol CE0686.21 by the PRISMA ethics committee (FWA00002055), and as protocol 2019-2142 by the Tulane University Institutional Review Board (FWA00002055). Parental written informed consent was obtained, in addition to the verbal and written assent for children ages 6 to 11 years.

Consent for publication

Not applicable.

Competing interests

All authors declare no competing interests or conflicts of interest.

Author details

1Laboratorio Satelite Iquitos, Asociación Benéfica Prisma, Área de Investigaciones Biomédicas, Calle Ramirez Hurtado Nº 622, Iquitos, Peru. 2Division of Infectious Diseases and International Health, Department of Internal Medicine, University of Virginia, MR-6 rm 2207, 545 Crispell Dr, Charlottesville, VA 22908, USA. 3Universidad Nacional de la Amazonia Peruana, Jirón Nauta, 16002 Iquitos, Peru. 4Facultad de Salud Pública y Administración, Universidad Peruana Cayetano Heredia, Av. Honorio Delgado, 430. San Martin de Porres, Lima, Peru. 5Department of Tropical Medicine, Tulane School of Public Health and Tropical Medicine, 1440 Canal Street, Suite 2310, New Orleans, LA 70112, USA.

Received: 29 April 2022 Accepted: 25 May 2022 Published online: 07 June 2022

References

1. Keller L, Welsche S, Patel C, Sayasone S, Ali SM, Ame SM, et al. Long-term outcomes of ivermectin–albendazole versus albendazole alone against soil-transmitted helminths: results from randomized controlled trials in Lao PDR and Pemba Island, Tanzania. PLoS Negl Trop Dis. 2021;15(6): e0009561.
2. Soil-transmitted helminth infections. 2022. https://www.who.int/news-room/fact-sheets/detail/soil-transmitted-helminth-infections. Accessed 26 Apr 2022.
3. Turner J, Badreddy M, Anemia—StatPearls—NCBI. Anemia. 2022. https://www.ncbi.nlm.nih.gov/books/NBK49994/. Accessed 26 Apr 2022.
4. Oliveira D, Ferreira FS, Atouguia J, Fortes F, Guerra A, Centeno-Lima S. Infection by intestinal parasites, stunting and anemia in school-aged children from southern Angola. PLoS ONE. 2015;10(9): e0137327.
5. Prevalence of anaemia in children aged 6–59 months (%). World Health Organization. 2022. https://www.who.int/data/gho/data/indicators/indicator-details/GHO/prevalence-of-anaemia-in-children-under-5-years. Accessed 26 Apr 2022.
6. Novianty S, Dimyati Y, Pasaribu S, Pasaribu AP. Risk factors for soil-transmitted helminthiasis in preschool children living in farmland, North Sumatera, Indonesia. J Trop Med. 2018;2018: e6706413.
7. Ministerio de Salud del Peru. Resolución Ministerial Nº 755–2017-MINSA. 2017. https://www.gob.pe/institucion/minsalas/normas-legales/188666-755-2017-Minsa.
8. Speich B, Ame SM, Ali SM, Alles R, Huwyler J, Hattendorf J, et al. Oxantel pamoate-albendazole for Trichuris trichiura infection. N Engl J Med. 2014;370(7):610–20.
9. Samuel F, Degarege A, Erko B. Efficacy and side effects of albendazole currently in use against Ascaris, Trichuris and hookworm among school children in Wondo Genet, southern Ethiopia. Parasitol Int. 2014;63(2):450–5.
10. Krücken J, Fraundorfer K, Mugisha JC, Ramünke S, Sifft KC, Geus D, et al. Reduced efficacy of albendazole against Ascaris lumbricoides in Rwandan schoolchildren. Int J Parasitol Drugs Drug Resist. 2017;7(3):262–71.
11. Levecke B, Easton AV, Coos P, Albionic M, Ame S, Gilleard JS, et al. The optimal timing of post-treatment sampling for the assessment of anthelmintic drug efficacy against Ascaris infections in humans. Int J Parasitol Drugs Drug Resist. 2018;8(1):67–9.
12. Gyorkos TW, Maheu-Giroux M, Blouin B, Casapia M. Impact of health education on soil-transmitted helminth infections in schoolchildren of the Peruvian Amazon: a cluster-randomized controlled trial. PLoS Negl Trop Dis. 2013;7(8):e2397. https://doi.org/10.1371/journal.pntd.0002397.

13. Gyorkos TW, Maheu-Giroux M, Blouin B, Saavedra L, Casapia M. Efficacia del Albendazol en dosis única sobre las infecciones por helmintos transmitidos por el suelo en escolares de una comunidad de líquitos, Perú. (Efficacy of a single dose of Albendazole for soil-transmitted helminth infections in school children of a village in Iquitos, Peru) Rev Peru Med Exp Salud Publica. 2013;30(4):601–7 (In Spanish).

14. Organización Panamericana de la Salud. Pautas operativas para la puesta en marcha de actividades integradas de desparasitación; 2015—OMS. https://www.paho.org/es/documentos/pautas-operativas-para-puesta-marcha-actividades-integradas-desparasitacion-2015. Accessed 13 Jan 2022.

15. Henriquez-Camacho C, Gotuzzo E, Echevarria J, White AC, Jr, Terashima A, Samalvides F, et al. Ivermectin versus albendazole or thiabendazole for Strongyloides stercoralis infection. Cochrane Database Syst Rev. 2016. https://doi.org/10.1002/14651858.CD007745.pub3.

16. Speich B, Ali SM, Arne S, Bogoš I, Alles R, Huwyler J, et al. Efficacy and safety of albendazole plus ivermectin, albendazole plus mebendazole, albendazole plus oxantel pamoate, and mebendazole alone against Trichuris trichiura and concomitant soil-transmitted helminth infections: a four-arm, randomised controlled trial. Lancet Infect Dis. 2015;15:277–84.

17. Diawara A, Halpenny CM, Churcher TS, Mwandawiro C, Khara J, Kaplan RM, et al. Association between response to albendazole treatment and β-tubulin genotype frequencies in soil-transmitted helminths. PLoS Negl Trop Dis. 2013;7(5):e2247.

18. Cabada MW, Lopez M, Arque E, Clinton WA. Prevalence of soil-transmitted helminths after mass albendazole administration in an indigenous community of the Manu jungle in Peru. Pathog Glob Health. 2014;108(4):200–5.

19. Molla E, Mamo H. Soil-transmitted helminth infections, anemia and undernutrition among schoolchildren in Yirgachiff, South Ethiopia. BMC Res Notes. 2018;11:585.

20. Palmeirim MS, Hürllimann E, Knopp S, Speich B, Belizario V, Joseph SA, et al. Efficacy and safety of co-administered ivermectin plus albendazole for treating soil-transmitted helminths: a systematic review, meta-analysis and individual patient data analysis. PLoS Negl Trop Dis. 2018;12(4):e0006458.

21. Matamoros G, Sánchez A, Gabrie JA, Juárez M, Ceballos L, Escalada A, et al. Efficacy and safety of albendazole and high-dose ivermectin coadministration in school-aged children infected with Trichuris trichiura in Honduras: a randomized controlled trial. Clin Infect Dis. 2021;73(7):1203–10.

22. Henriquez-Camacho C, Gotuzzo E, Echevarria J, White AC Jr, Terashima A, Samalvides F, et al. Ivermectin versus albendazole or thiabendazole for Strongyloides stercoralis infection. Cochrane Database Syst Rev. 2016;1.CD007745.

23. Patel C, Hürllimann E, Keller L, Hattendorf J, Sayasone S, Ali SM, et al. Efficacy and safety of ivermectin and albendazole co-administration in school-aged children infected with Trichuris trichiura in Côte d’Ivoire, Lao PDR and Pemba Island. In: Rollinson D, Stothard JR, editors., et al., Advances in parasitology. New York: Academic Press; 2021. p. 253–76.

24. Meja R, Vícuha Y, Broncano N, Sandoval C, Vaca M, Chico M, et al. A novel, multi-parallel, real-time polymerase chain reaction approach for eight gastrointestinal parasites provides improved diagnostic capabilities to resource-limited at-risk populations. Am J Trop Med Hyg. 2013;88(6):1041–7.

25. Booth M, Vounatsou P, Ngoran EK, Tanner M, Utzinger J. The influence of sampling effort and the performance of the Kato-Katz technique in diagnosing Schistosoma mansoni and hookworm co-infections in rural Côte divoire. Parasitology. 2003;127(6):525–32.

26. World Health Organization. Bench aids for the diagnosis of intestinal parasites. 2nd ed. Geneva: World Health Organization; 2019. p. 32.

27. World Health Organization. Bench aids for the diagnosis of intestinal parasites. 2nd ed. Geneva: World Health Organization; 2019. p. 32.

28. Wittek-McManus S, Simwanza J, Chisambi AB, Kepha S, Kamwendo Z, Mbwinja A, et al. Epidemiology of soil-transmitted helminths following sustained implementation of routine preventive chemotherapy: demographics and baseline results of a cluster randomised trial in southern Malawi. PLoS Negl Trop Dis. 2021;15(5):e0009292.

29. Vaz Nery S, Qi J, Llewellyn S, Clarke NE, Taubr R, Gray DJ, et al. Use of quantitative PCR to assess the efficacy of albendazole against Necator americanus and Ascariis spp. in Manufahi District, Timor-Leste. Parasites Vectors. 2018;11(1):373.

30. Easton AV, Oliveira RG, O’Connell EM, Kepha S, Mwandawiro CS, Njenga SM, et al. Multi-parallel qPCR provides increased sensitivity and diagnostic breadth for gastrointestinal parasites of humans: field-based inferences on the impact of mass deworming. Parasites Vectors. 2016;9(1):38.

31. Llewellyn S, Inpankaew T, Nery SV, Gray DJ, Verweij JJ, Clements ACA, et al. Application of a multiplex quantitative PCR to assess prevalence and intensity of intestinal parasite infections in a controlled clinical trial. PLoS Negl Trop Dis. 2016;10(11):e0004380. https://doi.org/10.1371/journal.pone.0258039.

32. Azzopardi KI, Hardy M, Baker C, Bonnici R, Llewellyn S, McCarthy JS, Taubr RJ, Steer AC. Detection of six soil-transmitted helminths in human stool by qPCR—a systematic workflow. PLoS ONE. 2021;16(9):e0258039. https://doi.org/10.1371/journal.pone.0258039.

33. Zendejas-Heredia PA, Colélla V, Hiš ŠF, Taubr RJ. Comparison of the egg recovery rates and limit of detection for soil-transmitted helminths using the Kato-Katz thick smear, faecal flotation and quantitative real-time PCR in human stool. PLoS Negl Trop Dis. 2021;15(5):e0009395. https://doi.org/10.1371/journal.pntd.0009395.

34. Walker M, Coops P, Albionico M, Arne SM, Ayana M, Dana D, et al. Individual responses to a single oral dose of albendazole indicate reduced efficacy against soil-transmitted helminths in an area with high drug pressure. PLoS Negl Trop Dis. 2021;15(10):e0009888.